DK3255042T3 - Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme - Google Patents

Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme Download PDF

Info

Publication number
DK3255042T3
DK3255042T3 DK16746826.3T DK16746826T DK3255042T3 DK 3255042 T3 DK3255042 T3 DK 3255042T3 DK 16746826 T DK16746826 T DK 16746826T DK 3255042 T3 DK3255042 T3 DK 3255042T3
Authority
DK
Denmark
Prior art keywords
same
pharmaceutical composition
heterocyclic compound
composition including
heterocyclic
Prior art date
Application number
DK16746826.3T
Other languages
English (en)
Inventor
Changhee Min
Byungkyu Oh
Yongeun Kim
Changmin Park
Original Assignee
Beyondbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondbio Inc filed Critical Beyondbio Inc
Application granted granted Critical
Publication of DK3255042T3 publication Critical patent/DK3255042T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DK16746826.3T 2015-02-04 2016-02-02 Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme DK3255042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150017339 2015-02-04
PCT/KR2016/001133 WO2016126085A2 (ko) 2015-02-04 2016-02-02 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
DK3255042T3 true DK3255042T3 (da) 2021-02-08

Family

ID=56564854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16746826.3T DK3255042T3 (da) 2015-02-04 2016-02-02 Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme

Country Status (14)

Country Link
US (3) US10227328B2 (da)
EP (1) EP3255042B1 (da)
JP (1) JP6615899B2 (da)
KR (1) KR101783642B1 (da)
CN (1) CN107250130B (da)
AU (1) AU2016216253B2 (da)
BR (1) BR112017016465B1 (da)
CA (1) CA2974788C (da)
DK (1) DK3255042T3 (da)
ES (1) ES2854707T3 (da)
IL (1) IL253538B (da)
RU (1) RU2710743C2 (da)
SG (1) SG11201705952SA (da)
WO (1) WO2016126085A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205459A1 (en) 2016-05-26 2017-11-30 Kalyra Pharmaceuticals, Inc. Egfr inhibitor compounds
US20210198238A1 (en) * 2018-08-30 2021-07-01 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
EA202191938A1 (ru) * 2019-01-29 2021-10-13 Бета Фарма, Инк. Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг
WO2021045582A1 (ko) * 2019-09-06 2021-03-11 비욘드바이오주식회사 2,6-비스-(2-아미노피리미딘-4-일)피리딘-3-올 2염산염 및 이를 포함하는 약제학적 조성물
WO2021045586A1 (ko) * 2019-09-06 2021-03-11 비욘드바이오주식회사 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물
KR20210029694A (ko) 2019-09-06 2021-03-16 비욘드바이오주식회사 2'-아미노-6-(2-아미노-6-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 2염산염 및 이를 포함하는 약제학적 조성물
KR102443873B1 (ko) * 2019-09-06 2022-09-19 비욘드바이오주식회사 피리미딘일 바이피리딘 화합물의 제조방법 및 그를 위한 중간체
TW202131917A (zh) * 2019-11-18 2021-09-01 日商中外製藥股份有限公司 併用醫藥
CN111558044B (zh) * 2020-06-01 2022-02-11 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种包含舒尼替尼的药物组合物及其制剂和应用
CN116082310A (zh) * 2023-02-17 2023-05-09 厦门大学 联吡啶酰胺类衍生物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
WO2001096308A1 (fr) * 2000-06-12 2001-12-20 Eisai Co., Ltd. Composes 1,2-dihydropyridine, leur procede de preparation et leur utilisation
US20030187007A1 (en) * 2001-05-30 2003-10-02 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
CN1742723A (zh) 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺-8-羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
WO2008106202A1 (en) * 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
WO2010018458A2 (en) * 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof

Also Published As

Publication number Publication date
KR101783642B1 (ko) 2017-10-10
IL253538A0 (en) 2017-09-28
AU2016216253A1 (en) 2017-08-17
WO2016126085A2 (ko) 2016-08-11
AU2016216253B2 (en) 2019-11-21
ES2854707T3 (es) 2021-09-22
US10227328B2 (en) 2019-03-12
JP2018504449A (ja) 2018-02-15
IL253538B (en) 2020-09-30
CA2974788A1 (en) 2016-08-11
CN107250130A (zh) 2017-10-13
NZ734084A (en) 2023-09-29
CA2974788C (en) 2023-04-11
JP6615899B2 (ja) 2019-12-04
US20180273510A1 (en) 2018-09-27
WO2016126085A3 (ko) 2016-11-03
BR112017016465B1 (pt) 2023-11-14
SG11201705952SA (en) 2017-09-28
CN107250130B (zh) 2019-11-08
RU2710743C2 (ru) 2020-01-10
EP3255042B1 (en) 2020-12-30
EP3255042A2 (en) 2017-12-13
RU2017130825A (ru) 2019-03-04
US10611754B2 (en) 2020-04-07
BR112017016465A2 (pt) 2018-06-19
US20200190062A1 (en) 2020-06-18
RU2017130825A3 (da) 2019-08-12
KR20160096033A (ko) 2016-08-12
US20190135786A1 (en) 2019-05-09
EP3255042A4 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
HK1255102A1 (zh) 雜環化合物及其應用
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
ES2841649T5 (es) Composición farmacéutica
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3412664T3 (da) Heterocyklisk sulfonamidderivat og medicin indeholdende samme